anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Comedone extraction provides greater satisfaction for acne treatment than conventional treatment alone; however, post-comedone extraction erythema (PCEE) remains a concern for patients.
OBJECTIVES: To evaluate the efficacy of pulsed-dye laser (PDL) in PCEE and comedone reduction.
METHODS: Mild-to-moderate acne patients were randomly allocated in split-face fashion. Three comedones were extracted on each facial side. On the PDL-treated side, 595-nm PDL was delivered to the entire side with an additional shot on three comedone-extracted sites. Erythema index (EI) and total acne lesion counts (TALC) were evaluated at baseline, week 2 and 4. The comprehensive acne severity scale (CASS) was assessed by three blinded independent pediatric dermatologists. Participant satisfaction surveys were completed at the end of the study.
RESULTS: Thirty-five participants (age 12.9-24.2 years) showed no differences in the EI and TALC at baseline on both sides. At weeks 2 and 4, the EI on the PDL-treated side was significantly lower (p < 0.001) with a greater EI reduction (p < 0.001) when compared to the control side regardless of gender and menstruation. There was significantly lower TALC on the PDL-treated side at week 2 (p < 0.001) and week 4 (p = 0.02). No complications were noted with high participant satisfaction reported (median 8; IQR 7-9). PDL remained significantly associated with EI improvements after controlling for gender, menstruation cycle, and examination stress.
CONCLUSION: PDL can be an adjunctive intervention for the treatment of PCEE and comedone reduction due to its effectiveness and high participant satisfaction.
Bupropion hydrochloride tablets are indicated for the treatment of major depressive disorder. A physician considering bupropion for the management of a patient’s first episode of depression should be aware that the drug may cause generalized seizures in a dose-dependent manner with an approximate incidence of 0.4% (4/1,000). This incidence of seizures may exceed that of other marketed antidepressants by as much as 4 fold. This relative risk is only an approximate estimate because no direct comparative studies have been conducted (see WARNINGS).

The efficacy of bupropion has been established in 3 placebo-controlled trials, including 2 of approximately 3 weeks’ duration in depressed inpatients and one of approximately 6 weeks’ duration in depressed outpatients. The depressive disorder of the patients studied corresponds most closely to the Major Depression category of the APA Diagnostic and Statistical Manual III.

Major Depression implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigability, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicidal ideation or attempts.

Effectiveness of bupropion in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use bupropion for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.
FIELD: medicine. SUBSTANCE: agent for oral administration consists of two hormonal components placed in container. The first component consists of 5-14 daily doses containing estrogen; the second component consists of 23-14 daily doses containing the combination of estrogen compound and gestogen. One daily dose of each component has estrogen compound at dose effective for follicle maturation destroying; one daily dose of the second component has gestogen compound at amount sufficient for ovulation inhibition. Number of the first daily doses component is less then that of the second component. EFFECT: enhanced effectiveness of agent. 8 cl
Primary inguinal hernia is a common pediatric surgical condition with an incidence of 1%-4%, which is higher in male or premature newborns. It is characterized by the protrusion of abdominal contents through inguinal canal in newborns. However, prenatal fetal inguinal hernia is a rare condition because the pressure of amniotic fluid is similar to intra-abdominal pressure. Only 19 English publications were found with 21 reported cases until now. We report belatedly discovered inguinoscrotal hernia at 38+0 weeks' gestation. Usually, the fetal testicular descent begins from 24 to 25 weeks' gestation, and it is found after 32 weeks of gestational age in 97% of the fetuses. Therefore, it is necessary to get into the habit of checking fetal testicles during routine US after at least 32 weeks of gestational age.
The invention discloses an application of KGF-2 in preparing a medicine for treating skin dysfunction. Belongs to the technical field of medicine. The invention discloses an application of KGF-2 in preparing a medicine for treating skin dysfunction, wherein scar tissues are characterized by compact collagen fibers, vigorous extracellular matrix secretion and low KGF-2 expression. KGF-2 can significantly inhibit mechanical stress-induced scar formation in mice, and reduce the expression of extracellular matrix of primary fibroblasts. Whereas STAP2 plays a key role in the process of scar formation. KGF-2 regulates the expression of STAP2 through P38, and further regulates the level of P-STAT3, thereby influencing the expression of downstream fibrosis-related proteins and reducing the formation of scars. KGF-2 holds promise as an effective agent for the prevention of scarring.
Persistent infection with high-risk human papillomavirus (HR-HPV) is the primary and initiating factor for cervical cancer. With over 200 identified HPV types, including 14 high-risk types that integrate into the host cervical epithelial cell DNA, early determination of HPV infection type is crucial for effective risk stratification and management. Presently, on-site immediate testing during the HPV screening stage, known as Point of Care Testing (POCT), remains immature, severely limiting the scope and scenarios of HPV screening. This study, guided by the genomic sequence patterns of HPV, established a multiplex recombinase polymerase amplification (RPA) technology based on the concept of "universal primers." This approach achieved the multiple amplification of RPA, coupled with the CRISPR/Cas12a system serving as a medium for signal amplification and conversion. The study successfully constructed a POCT combined detection system, denoted as H-MRC12a (HPV-Multiple RPA-CRISPR/Cas12a), and applied it to high-risk HPV typing detection. The system accomplished the typing detection of six high-risk HPV types (16, 18, 31, 33, 35, and 45) can be completed within 40 min, and the entire process, from sample loading to result interpretation, can be accomplished within 45 min, with a detection depth reaching 1 copy/μL for each high-risk type. Validation of the H-MRC12a detection system's reproducibility and specificity was further conducted through QPCR on 34 clinical samples. Additionally, this study explored and optimized the multiplex RPA amplification system and CRISPR system at the molecular mechanism level. Furthermore, the primer design strategy developed in this study offers the potential to enhance the throughput of H-MRC12a detection while ensuring sensitivity, providing a novel research avenue for high-throughput detection in Point-of-Care molecular pathogen studies.
The group will be given a standard scripted verbal and identical written instructions plus the study group will be shown a 5-minute educational video (available at https://youtu.be/rvYfDc-Yfus ) which depicts key components of entering data on the diary. Patients in this group will also have online access to the video when they are filling out their diaries.
Pravastatin has been administered concurrently with cholestyramine, colestipol, nicotinic acid, probucol and gemfibrozil. Preliminary data suggest that the addition of either probucol or gemfibrozil to therapy with lovastatin or pravastatin is not associated with greater reduction in LDL-cholesterol than that achieved with lovastatin or pravastatin alone. No adverse reactions unique to the combination or in addition to those previously reported for each drug alone have been reported. Myopathy and rhabdomyolysis (with or without acute renal failure) have been reported when another HMG-CoA reductase inhibitor was used in combination with immunosuppressive drugs, gemfibrozil, erythromycin, or lipid-lowering doses of nicotinic acid. Concomitant therapy with HMG-CoA reductase inhibitors and these agents is generally not recommended. (See WARNINGS: Skeletal Muscle and PRECAUTIONS: Drug Interactions.)
The invention relates to a Salmonella typhi gene deletion strain, a vaccine prepared from the Salmonella typhi gene deletion strain and application of the strain. The bacterial strain is Salmonella typhi delta crpST-1 and preserved in the China center for type culture collection, and the preservation number is CCTCC NO: M2011373. The Salmonella typhi gene deletion strain disclosed by the invention has excellent immunizing protection efficacy and weak toxicity without any adverse side effect on immunized pigs and is safer compared with the traditional vaccine. Therefore, the vaccine which is prepared from the gene deletion strain built by a parent strain has wide market application prospect. In addition, the Salmonella typhi gene deletion strain disclosed by the invention retains the immune protective efficacy aiming to salmonella typhi infection, and has clear genetic background and stable characteristics, so that the Salmonella typhi gene deletion strain has better biosecurity. The Salmonella typhi gene deletion strain disclosed by the invention does not contain a resistance tag and totally accords with the biological security requirement of vaccine.
The invention discloses attapulgite sun powder for men. The key point of the technical proposal of the invention is that the attapulgite sun powder for men is prepared from purified attapulgite clay, medlar, grape pip, honeysuckle flowers, 2-hydroxy-4-methoxybenzophenone, rutile type titanium dioxide, menthol and glyceryl monostearate. The preparation method of the attapulgite sun powder for men comprises the following steps: mixing the ingredients of the attapulgite sun powder for men; feeding the mixture into a crusher to crush the mixture; feeding the crushed mixture into a superfine pulverizer to pulverize the crushed mixture; and packing the pulverized mixture to obtain the finished product of the attapulgite sun powder for men. The attapulgite sun powder for men has high antioxidant capacity, prevents and improves pigment precipitation in skin caused by ultraviolet exposure and improves a skin fitness effect. The attapulgite sun powder for men can keep skin cool and relaxing when used and is suitable to be used during long-time outdoor activities. The attapulgite sun powder for men is suitable to be applied on exposed skins of men.
Formulations of amorphous complexes of compounds of formula (I), such as isogranulatimide or granulatimide, with at least one cyclodextrin are disclosed. Said formulations further comprise a water- soluble compound for inducing osmosis, such as dextrose and/or sodium chloride. Also provided are methods for preparing the aforementioned formulations and methods for delivery in  in vitro  and  in vivo  applications. The formulations may be suitable for cancer indications where it is desired to enhance the cytotoxic effectiveness of anti-cancer drugs such as DNA damaging or anti-mitotic agents. In addition, these formulations may be suitable for cancer indications where it is desired to increase the effectiveness of radiotherapy. In the compounds of formula (I), W is defined as being a group of formula (i) or (ii) in which K, E and T are independently N, CR or CZ; Q is NR 2 , O, S or C(R) 2 ; R 1  is R, RCO- or ArCO-; X and Y are O, H, OH or H 2  and R, Z, R 2  and Ar are as defined in claim 1.
Children will continue their therapeutic dose of LDX during the DBPC phase (which is determined during the titration phase). Before each testing session there will be a washout period of at least 48 hours; the placebo will be given the morning of the testing at the DRUG unit. For blinding purpose we will blindfold the children when taking placebo at the DRUG unit.
INTRODUCTION: Histopathological findings of chronic active T-cell-mediated rejection (CA-TCMR) have been reported to potentially improve with treatment. However, whether this improvement is associated with a better renal prognosis remains unclear. This study was performed to analyze the impact of the histological response to therapy on kidney allograft survival in patients with CA-TCMR.
METHODS: The data of patients diagnosed with CA-TCMR between January 2018 and May 2023 were retrospectively reviewed. A composite graft endpoint was defined as a two-fold increase in the serum creatinine level or the development of end-stage kidney disease.
RESULTS: Thirty-seven patients with CA-TCMR underwent 46 follow-up biopsies. Eleven patients who were diagnosed with CA-TCMR at the last biopsy were classified as the persistent group, while the remaining 26 patients were classified as the transient group. Both before and after treatment, there were no significant changes in serum creatinine, estimated glomerular filtration rate, or proteinuria in either group. However, the transient group showed a significant reduction in interstitial fibrosis and tubular atrophy without a specific etiology (IFTA). This improvement was attributed to better histopathological Banff scores after treatment. Patients with persistent CA-TCMR had significantly worse graft survival than those with transient CA-TCMR (p = 0.002), even after adjusting for significant clinical factors (hazard ratio: 11.4; 95% CI: 1.1-120.0; p = 0.043).
CONCLUSION: Our findings suggest that the persistence of histopathologic evidence of CA-TCMR after treatment is a significant risk factor for allograft loss compared with transient CA-TCMR.
OBJECTIVE: We aimed to investigate sleep in children with drug-resistant epilepsy (DRE), including developmental and epileptic encephalopathies (DEEs). Next, we examined differences in sleep macrostructure and microstructure and questionnaire outcomes between children with well-controlled epilepsy (WCE) and children with DRE. Furthermore, we wanted to identify factors associated with poor sleep outcome in these children, as some factors might be targets to improve epilepsy and neurodevelopmental outcomes.
METHODS: A cross-sectional study was conducted in children 4 to 18-years-old. Children without epilepsy, with WCE, and with DRE were included. Overnight electroencephalography (EEG), including chin electromyography and electrooculography, to allow sleep staging, was performed. Parents were asked to fill out a sleep questionnaire. Classical five-stage sleep scoring was performed manually, spindles were automatically counted, and slow wave activity (SWA) in the first and last hour of slow wave sleep was calculated.
RESULTS: One hundred eighty-two patients were included: 48 without epilepsy, 75 with WCE, and 59 with DRE. We found that children with DRE have significantly lower sleep efficiency (SE%), less time spent in rapid eye movement (REM) sleep, fewer sleep spindles, and a lower SWA decline over the night compared to children with WCE. Subjectively more severe sleep problems were reported by the caregivers and more daytime sleepiness was present in children with DRE. Least absolute shrinkage and selection operator (LASSO) regression showed that multifocal interictal epileptiform discharges (IEDs), benzodiazepine treatment, and longer duration of epilepsy were associated with lower SE% and lower REM sleep time. The presence of multifocal discharges and cerebral palsy was associated with fewer spindles. Benzodiazepine treatment, drug resistance, seizures during sleep, intellectual disability, and older age were associated with lower SWA decline.
SIGNIFICANCE: Both sleep macrostructure and microstructure are severely impacted in children with DRE, including those with DEEs. Epilepsy parameters play a distinct role in the disruption REM sleep, spindle count, and SWA decline.
PURPOSE:The titled solution effective for excess acid in the stomach, being administered easily, keeping stable suspension state easily, showing improved redispersion state even if it is stored for a long period, obtained by adding a suspension and an amino acid to an antacid. CONSTITUTION:An antacid is blended with a suspension and an amino acid, to obtain an internal solution containing stable antacid. Magnesium aluminate silicate, synthetic hydrotalcite, etc. having 0.01-20mu, preferably 0.01-10mu particle diameter are used as the antacid. 0.005-5w/v% CMC-Na, etc. is used as the suspension. 0.005-5w/v% alanine, alginine, glycine, etc. may be used as the amino acid. Since the antacid is suspended in a fine particle state, this solution shows antacid effect more rapidly than solid pharmaceutical preparation, has higher covering effect on stomach mucosa, and it is a drug more useful than solid pharmaceutical preparation. This solution is stable to long-period preservation, shows improved redispersion properties and is useful as a drug.
The aim of the invention is to develop a novel dosage form for the external therapy of psoriasis during acute periods of the disease. The agent for the external therapy of psoriasis is characterised in that the preparations of methylxathine group, the selenium and some other preparations are used as active substances, a fatty base, refined oil and water being used as adjuvants. The food additive  Lecithin  mixed with cholesterol at a ratio of 1:1 with respect to phosphatidylcholine is dissolved in chloroform. Chloroform being evaporated, a solution containing the inventive active substances is introduced into a flask. Afterwards, the content of the flask is continuously agitated at a temperature ranging from 36 to 40 °C. As a result of that process, a liposomal emulsion is obtained. The fatty base (lanolin) and a vegetable oil, for example olive oil being added and mixed, the final product is produced in the form of a cream having the specified consistence. The inventive agent is also characterised in that it can be used during acute periods of the disease when other agents, including coal tar and anthralin, are contraindicated and for treating exudative psoriasis and psoriasis of the scalp when the known therapeutic agents are inefficient.
Participants will receive a dose of 40 or 60 mg of selinexor oral tablets on Days 1, 8, and 15 for Cycle 1 to 12 during primary treatment and 40 (dose level 1) then 60 mg (dose level 2) during continuous treatment (each cycle consists of 28 days). During the primary treatment, participants will also receive lenalidomide oral dose of 25 mg once daily on Days 1 to 21, and tafasitamab IV dose of 12 mg/kg on Days 1, 8, 15, and 22 for Cycle 1 to 3 and Days 1 and 15 for Cycle 4 to 12. Participants will also receive an IV dose of tafasitamab 12 mg/kg on Days 1 and 15 for all dose levels during the continuous treatment.
A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training. After the follow-up measurement opportunity to participate in the program.
The invention relates to nanotechnology. The carbon-bearing nanoparticle consists of a cubical carbon monocrystal nucleus, the size of which is equal to or less than 4 nm, and a monocrystalline carbon shell having an SP 3  structure and a thickness ranging from 0.19 to 0.2 nm. The method for producing carbon-bearing NSP 3  nanoparticles involves exploding a charge of blasting material having a negative oxygen balance. The charge is preliminary surrounded by ice with a temperature less than minus 25° C. The ratio of the mass of the ice to the mass of the explosive charge is of 1:4-6. The suspension of carbon-bearing nanoparticles produced as a result of explosion is chemically purified. The thus produced suspension is disaggregated by being repeatedly frozen to a temperature lower than the liquid hydrogen boiling point. Once the suspension has been disaggregated, it is exposed to the action of ultrasonic waves with a frequency of 18-27 Hz for 5-18 minutes. The blasting material consists of a trinitrotoluene and cyclonite mixture and is in the form a cylinder-shaped plastic mixture with a ratio of the cylinder diameter to the height thereof of 1:6. The method for chemically purifying the suspension involves removing metal impurities from the suspension by heating it for 5-7 hours in a 10-25% nitric acid solution.
Hypoxia, especially the chronic type, leads to disruptive results in the brain that may contribute to the pathogenesis of some neurodegenerative diseases such as Alzheimer's disease (AD). The ventrolateral medulla (VLM) contains clusters of interneurons, such as the pre-Bötzinger complex (preBötC), that generate the main respiratory rhythm drive. We hypothesized that exposing animals to chronic sustained hypoxia (CSH) might develop tauopathy in the brainstem, consequently changing the rhythmic manifestations of respiratory neurons. In this study, old (20-22 months) and young (2-3 months) male rats were subjected to CSH (10 ± 0.5% O2) for ten consecutive days. Western blotting and immunofluorescence (IF) staining were used to evaluate phosphorylated tau. Mitochondrial membrane potential (MMP or ∆ψm) and reactive oxygen species (ROS) production were measured to assess mitochondrial function. In vivo diaphragm's electromyography (dEMG) and local field potential (LFP) recordings from preBötC were employed to assess the respiratory factors and rhythmic representation of preBötC, respectively. Findings showed that ROS production increased significantly in hypoxic groups, associated with a significant decline in ∆ψm. In addition, tau phosphorylation elevated in the brainstem of hypoxic groups. On the other hand, the power of rhythms declined significantly in the preBötC of hypoxic rats, parallel with changes in the respiratory rate, total respiration time, and expiration time. Moreover, there was a positive and statistically significant correlation between LFP rhythm's power and inspiration time. Our data showed that besides CSH, aging also contributed to mitochondrial dysfunction, tau hyperphosphorylation, LFP rhythms' power decline, and changes in respiratory factors.